European Commission Approves Incyte’s Povofortay for Hidradenitis Suppurativa
The European Commission approved Povofortay (povorcitinib) 45 mg and 75 mg for eligible adults with moderate to severe hidradenitis suppurativa.
The European Commission approved Povofortay (povorcitinib) 45 mg and 75 mg for eligible adults with moderate to severe hidradenitis suppurativa.